Drug Trial Radar · NCT03447314
Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Sep 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
54
Actual
Start
Mar 26, 2018
Primary completion
Jul 1, 2020
Study completion Mar 11, 2022
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- IQVIA Pty Ltd
- First posted
- Feb 27, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
GSK1795091 is being developed for administration in combination with other immune system modulators for the treatment of cancers. The study will be conducted in two parts. In Part 1, dose escalation will be performed to identify combination dose levels comprising GSK1795091 with either 24 milligrams (mg) GSK3174998 (Part 1a), 80 mg GSK3359609 (Part 1b), or 200 mg pembrolizumab (Part 1c). One dose level of GSK3174998, GSK3359609, or pembrolizumab with up to 5 dose levels of GSK1795091 are planned for evaluation. In Part 2 (dose-expansion), subjects will receive a single dose level of GSK1795091 as identified based on data from Part 1, in combination with either GSK3174998, GSK3359609, or pembrolizumab.
Conditions
- Neoplasms
Interventions
GSK1795091Drug
GSK1795091 will be available as solution for injection
GSK3174998Drug
GSK3174998 will be available as lyophilized powder to be reconstituted for infusion.
GSK3359609Drug
GSK3359609 will be available as solution for infusion.
PembrolizumabDrug
Pembrolizumab will be available as solution for infusion or lyophilized powder for reconstitution.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs (STEAEs)Time frame: Up to 27 months
- Part 2: Number of Participants With TEAEs and STEAEsTime frame: Up to 27 months
- Part 1: Number of Participants With Dose-limiting Toxicity (DLT)Time frame: 42 days
- Part 1: Number of Participants With TEAEs Leading to DiscontinuationTime frame: Up to 2 years
- Part 2: Number of Participants With TEAEs Leading to DiscontinuationTime frame: Up to 2 years
- Part 1: Number of Participants With TEAEs Leading to Dose Reductions or Dose DelaysTime frame: Up to 2 years
- Part 2: Number of Participants With TEAEs Leading to Dose Reductions or Dose DelaysTime frame: Up to 2 years
- Part 1: Number of Participants With Change From Baseline in Hematology Parameters With Respect to the Normal RangeTime frame: Baseline (Day 1: Pre-dose) and up to 2 years
- Part 2: Number of Participants With Change From Baseline in Hematology Parameters With Respect to the Normal RangeTime frame: Baseline (Day 1: Pre-dose) and up to 2 years
- Part 1: Number of Participants With Change From Baseline in Chemistry Parameters With Respect to the Normal RangeTime frame: Baseline (Day 1: Pre-dose) and up to 2 years
- Part 2: Number of Participants With Change From Baseline in Chemistry Parameters With Respect to the Normal RangeTime frame: Baseline (Day 1: Pre-dose) and up to 2 years
- Part 1: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range CriteriaTime frame: Up to 2 years
- Part 2: Number of Participants With Worst Case Urinalysis Results Relative to Normal Range CriteriaTime frame: Up to 2 years
- Part 1: Number of Participants With Increase From Baseline in Vital Signs According to Markedly Abnormal CriteriaTime frame: Up to 2 years
- Part 2: Number of Participants With Vital Signs Any Increases From Baseline According to Markedly Abnormal CriteriaTime frame: Up to 2 years
- Part 1: Number of Participants With Any Decrease From Baseline in Vital Sign According to Markedly Abnormal CriteriaTime frame: Up to 2 years
- Part 2: Number of Participants With Vital Signs Any Decreases From Baseline According to Markedly Abnormal CriteriaTime frame: Up to 2 years
- Part 1: Number of Participants With Any Increase From Baseline in Corrected QT Interval Using Fredericia's Formula (QTcF) According to Markedly Abnormal CriteriaTime frame: Up to 2 years
- Part 2: Number of Participants With Any QTcF Interval Increases From Baseline According to Markedly Abnormal CriteriaTime frame: Up to 2 years
Locations
8 sites in 4 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Boston, Massachusetts
GSK Investigational Site
St Louis, Missouri
GSK Investigational Site
Dallas, Texas
GSK Investigational Site
Houston, Texas
GSK Investigational Site
Tacoma, Washington
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Amsterdam, Netherlands
GSK Investigational Site
Barcelona, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.